2025 Q4 -tulosraportti
28 päivää sitten
‧49 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.3. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 | ||
2024 Q4 -tulosraportti 1.4.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10.3.Anyone know anything?
·1 päivä sittenEvaxion talks and talks and it's all hot air. All the time they are busy with something new, but nothing ever becomes a reality. Perhaps because they are unable to focus on anything at all. Perhaps because it's all a big bluff. Look at their pipeline. At least 10 different projects, but not a single one with a completed phase 2! And it is precisely in phase 2 that they must prove that what they are tinkering with can actually be used.
29.1.29.1.3 ord IS I MAVEN·26.2.It really requires a lot of patience by now 😂😂
·29.1.I must admit that even after having been heavily exposed to them since the IPO and bought up through the years, one must probably soon realize they do not aim to create a healthy business – unfortunately, not enough focus on commercial profiles in the company. Their performance is deeply unacceptable even for biotech, and even with a brilliant pipeline – more capable people at the helm would have secured them a market cap immensely larger than is currently the case. And finally, I believe their investor relations are as poor as anything can be, with dilution hidden under results presentations, and the release of new results over the weekend – it screams to high heaven.·2.2.Completely agree. They have a good pipeline, and have a platform that is quite exciting - although that "space" is becoming more and more "crowded". Their communication about transforming the technical into a good business, however, is to say the least, abysmal. The announcement that their "AI immunology platform" is being expanded for the exploration of autoimmune diseases without explaining the business part was both poorly timed and directly unfortunate. Communication regarding their two-legged gonorrhea strategy I found amateurish. Cut off one leg, and continue with mRNA. So focus and clarity on the path to earnings is very much missed - preferably with a business person with clarity in their message.·2.2.Completely and utterly agree with you. Hard to see anything other than it will bleed down to $2, not exactly any major events in store. One can hope for an unexpected milestone payment on the options agreement, but if not, they will soon have to go to the printer again - and then they will have destroyed everyone's trust in them as a company in my eyes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
28 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10.3.Anyone know anything?·1 päivä sittenEvaxion talks and talks and it's all hot air. All the time they are busy with something new, but nothing ever becomes a reality. Perhaps because they are unable to focus on anything at all. Perhaps because it's all a big bluff. Look at their pipeline. At least 10 different projects, but not a single one with a completed phase 2! And it is precisely in phase 2 that they must prove that what they are tinkering with can actually be used.
- 29.1.29.1.3 ord IS I MAVEN·26.2.It really requires a lot of patience by now 😂😂
- ·29.1.I must admit that even after having been heavily exposed to them since the IPO and bought up through the years, one must probably soon realize they do not aim to create a healthy business – unfortunately, not enough focus on commercial profiles in the company. Their performance is deeply unacceptable even for biotech, and even with a brilliant pipeline – more capable people at the helm would have secured them a market cap immensely larger than is currently the case. And finally, I believe their investor relations are as poor as anything can be, with dilution hidden under results presentations, and the release of new results over the weekend – it screams to high heaven.·2.2.Completely agree. They have a good pipeline, and have a platform that is quite exciting - although that "space" is becoming more and more "crowded". Their communication about transforming the technical into a good business, however, is to say the least, abysmal. The announcement that their "AI immunology platform" is being expanded for the exploration of autoimmune diseases without explaining the business part was both poorly timed and directly unfortunate. Communication regarding their two-legged gonorrhea strategy I found amateurish. Cut off one leg, and continue with mRNA. So focus and clarity on the path to earnings is very much missed - preferably with a business person with clarity in their message.·2.2.Completely and utterly agree with you. Hard to see anything other than it will bleed down to $2, not exactly any major events in store. One can hope for an unexpected milestone payment on the options agreement, but if not, they will soon have to go to the printer again - and then they will have destroyed everyone's trust in them as a company in my eyes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.3. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 | ||
2024 Q4 -tulosraportti 1.4.2025 |
2025 Q4 -tulosraportti
28 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.3. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 | ||
2024 Q4 -tulosraportti 1.4.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10.3.Anyone know anything?·1 päivä sittenEvaxion talks and talks and it's all hot air. All the time they are busy with something new, but nothing ever becomes a reality. Perhaps because they are unable to focus on anything at all. Perhaps because it's all a big bluff. Look at their pipeline. At least 10 different projects, but not a single one with a completed phase 2! And it is precisely in phase 2 that they must prove that what they are tinkering with can actually be used.
- 29.1.29.1.3 ord IS I MAVEN·26.2.It really requires a lot of patience by now 😂😂
- ·29.1.I must admit that even after having been heavily exposed to them since the IPO and bought up through the years, one must probably soon realize they do not aim to create a healthy business – unfortunately, not enough focus on commercial profiles in the company. Their performance is deeply unacceptable even for biotech, and even with a brilliant pipeline – more capable people at the helm would have secured them a market cap immensely larger than is currently the case. And finally, I believe their investor relations are as poor as anything can be, with dilution hidden under results presentations, and the release of new results over the weekend – it screams to high heaven.·2.2.Completely agree. They have a good pipeline, and have a platform that is quite exciting - although that "space" is becoming more and more "crowded". Their communication about transforming the technical into a good business, however, is to say the least, abysmal. The announcement that their "AI immunology platform" is being expanded for the exploration of autoimmune diseases without explaining the business part was both poorly timed and directly unfortunate. Communication regarding their two-legged gonorrhea strategy I found amateurish. Cut off one leg, and continue with mRNA. So focus and clarity on the path to earnings is very much missed - preferably with a business person with clarity in their message.·2.2.Completely and utterly agree with you. Hard to see anything other than it will bleed down to $2, not exactly any major events in store. One can hope for an unexpected milestone payment on the options agreement, but if not, they will soon have to go to the printer again - and then they will have destroyed everyone's trust in them as a company in my eyes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt